Patents by Inventor Rajeev Bhide

Rajeev Bhide has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

NOVEL INHIBITORS OF KINASES

Publication number: 20070299075

Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

Type: Application

Filed: August 2, 2007

Publication date: December 27, 2007

Inventors: Rajeev Bhide, Zhen-Wei Cai, Ligang Qian, Stephanie Barbosa, Louis Lombardo, Jeffrey Robl
Heterocyclic inhibitors of kinases

Publication number: 20060135576

Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

Type: Application

Filed: February 8, 2006

Publication date: June 22, 2006

Inventors: Robert Borzilleri, Rajeev Bhide, John Tokarski, Peter Zheng, Ligang Qian, Zhen-Wei Cai
Pyrrolotriazine inhibitors of kinases

Publication number: 20060128709

Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

Type: Application

Filed: February 2, 2006

Publication date: June 15, 2006

Inventors: John Hunt, Rajeev Bhide, Robert Borzilleri, Ligang Qian
Azaindole kinase inhibitors

Publication number: 20060058304

Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

Type: Application

Filed: August 29, 2005

Publication date: March 16, 2006

Inventors: Rajeev Bhide, Rejean Ruel, Carl Thibault, Alexandre L'Heureux
Pyrrolotriazine kinase inhibitors

Publication number: 20060009454

Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

Type: Application

Filed: June 14, 2005

Publication date: January 12, 2006

Inventors: Zhen-wei Cai, Louis Lombardo, Rajeev Bhide, Ligang Qian, Donna Wei, Stephanie Barbosa
Pyrrolotriazine inhibitors of kinases

Publication number: 20060004007

Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

Type: Application

Filed: July 27, 2005

Publication date: January 5, 2006

Inventors: John Hunt, Rajeev Bhide, Robert Borzilleri, Ligang Qian
Pyrrolotriazine kinase inhibitors

Publication number: 20050234060

Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

Type: Application

Filed: June 21, 2005

Publication date: October 20, 2005

Inventors: Rajeev Bhide, Robert Borzilleri
Novel inhibitors of kinases

Publication number: 20050124621

Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

Type: Application

Filed: January 13, 2005

Publication date: June 9, 2005

Inventors: Rajeev Bhide, Zhen-Wei Cai, Ligang Qian, Stephanie Barbosa, Louis Lombardo, Jeffrey Robl
Inhibitors of farnesyl protein transferase

Patent number: 6455523

Abstract: Inhibition of farnesyl transferase, which is an enzyme involved in ras ocogene expression, is effected by compounds of the formulas their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof inhibit farnesyl protein transferase which is an enzyme involved in ras oncogene expression.

Type: Grant

Filed: August 13, 1999

Date of Patent: September 24, 2002

Assignee: Bristol-Myers Squibb Company

Inventors: Charles Z. Ding, Soong-Hoon Kim, John T. Hunt, Toomas Mitt, Rajeev Bhide, Katerina Leftheris
Inhibitors of farnesyl protein transferase

Patent number: 6011029

Abstract: The present invention comprises benzodiazepine compounds having farnesyl transferase inhibitory activity.

Type: Grant

Filed: February 20, 1997

Date of Patent: January 4, 2000

Assignee: Bristol-Myers Squibb Company

Inventors: Charles Z. Ding, Soong-Hoon Kim, John T. Hunt, Toomas Mitt, Rajeev Bhide, Katerina Leftheris